Human Clinical Trial Results and Key Benefits
Phytofare Catechin Complex is Superior to Generic Green Tea Extracts
LONDON, UNITED KINGDOM, April 10, 2018 (GLOBE NEWSWIRE) -- Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, today provided an update and recap of its bioavailability and the science and key benefits of Phytofare from previous human clinical trial results.
Previous results of performed human clinical trials have demonstrated Phytofare® Catechin complex to be superior to generic green tea extracts in three significant categories: increased bioavailability (absorption), longer residence time in the blood plasma, and delivery of the full catechin profile.
According to the trial results, Phytofare® delivered an average catechin concentration of 14,786 ng/ml compared to a concentration of 930 ng/ml delivered by the standard green tea extract. This is almost a 15-fold greater average concentration than was delivered by the generic comparator. The total concentration of Epigallocatechin Gallate (EGCG) delivered by Phytofare was 153,011 ng/ml compared to a total concentration of 15,921 ng/ml EGCG delivered by the standard green tea extract, a 10-fold greater total concentration. EGCG is regarded as a key catechin and has been linked to a variety of possible wellness effects, including weight loss, anti-viral activity, cancer prevention, and blood sugar regulation in diabetics.
With respect to blood plasma residency, Phytofare® was still active in the system 24 hours after consumption. In the case of EGCG, after 24 hours the Phytofare® levels were 256ng/ml compared to 16ng/ml for the generic, a 16-fold increase. In fact, after 24 hours there was still nearly 1.5 times as much Phytofare® EGCG in the blood as was present from the generic extract at its highest recorded level (265ng/ml compared to 181ng/ml). This means that a therapeutic level of Phytofare® can be achieved from a once-per-day dose whilst standard green tea would require multiple doses of far greater size throughout the day to deliver the same levels of catechins. Where catechins consumed at high levels (greater than 800mg) can cause nausea and other side effects, being able to deliver therapeutic levels with a smaller dose is a huge benefit to the consumer.
Thirdly, the clinical trial showed that all eight primary catechins were present in the blood from the Phytofare®, while only three catechins were detected with the generic. This means that consumers get the synergistic effects of the entire phytonutrient profile with Phytofare® whereas these benefits are lost with generic extract through processing and metabolization.
The following conclusions can be drawn from the results obtained in this study:
- There is no doubt that the plasma levels of catechins are substantially and statistically enhanced as a result of the Phytofare® extraction process when compared to that observed for a commercial green tea extract;
- While overall Phytofare® exhibited 15 times greater bioavailability, the enhancement in plasma levels from Phytofare® was not equal for all the catechins analyzed. The improvement ranged from 8 times to 62 times. This large variation may in part be ascribed to the low values of certain catechins found in the generic extract.
- The catechin found at the highest concentration for both the commercial and Phytofare® product was epigallocatechin gallate (EGCG).
- The plasma levels observed after administration of the Phytofare® product did not return to zero within 24 hours of administration. In practice this means that the circulating half-life of the Phytofare® catechins is much longer than generic and that a baseline level for catechins can be maintained when using the current dosing intervals.
When looking at the study results in their totality, they paint a clear picture of the benefits of The Phytofare® over a generic ECGC or green tea extract:
Phytofare® is clinically proven to be 15X more bioavailable than generic green tea extract – this is the only bioavailability study of its kind in the world.
- Phytofare® is clinically proven to have a blood residence time of over 24 hours.
- All 8 catechins present in a highly bioavailable form compared to the 3 present in generic green tea extract
- Phytofare® production is vertically integrated - all aspects of farming and production are controlled by Plandai Biotechnology Inc. from the growing of the plant through to the production of the extract. This ensures consistent quality and quantity.
- Each batch of Phytofare® undergoes extensive independent third-party analysis to guarantee quality and safety
- Cost per dose of Phytofare® is on par, if not lower than generic. This means that consumers can get far superior results for less than the price of a generic.
- Due to the lower dosage required, Phytofare® enables the nutraceutical manufacturers to free up capsule space for other active ingredients.
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company's products include animal husbandry, dietary supplements and diabetes. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit: http://www.plandaibiotech.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.